Soleil Securities Reiterates Buy on Arena Pharmaceuticals (ARNA)
Tweet Send to a Friend
Soleil Securities Group reiterates its Buy rating and $16 price target on Arena Pharmaceuticals (Nasdaq: ARNA).
The firm ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
The firm ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
